Talk:Raymond Schinazi

This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.

If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page.

Biography: Science and Academia

	Biography portal This article is within the scope of WikiProject Biography, a collaborative effort to create, develop and organize Wikipedia's articles about people. All interested editors are invited to join the project and contribute to the discussion. For instructions on how to use this banner, please refer to the documentation.BiographyWikipedia:WikiProject BiographyTemplate:WikiProject Biographybiography articles
	This article is supported by the science and academia work group.
	An appropriate infobox may need to be added to this article. Please refer to the list of biography infoboxes for further information.

Medicine Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.
	This article has been marked as needing an infobox.

Contributions to sofosbuvir

Schinazi's contribution to the discovery of sofosbuvir is contentious. He is the co-author of a 2005 paper that discovered a precursor to the drug.^[1] Jean-Pierre Sommadossi, a principal founder of Idenix and a co-founder of Pharmasset, has stated that Schinazi “wasn't involved with anything” in the actual development of sofosbuvir. Schinazi's former business partner no longer speaks to him.^[1]^[2]

Previous material violates Wikipedia Policy. The point of view was not neutral and the statements are not well sourced. One statement is merely opinion. Selected fragments of source material have been taken and are presented in a contentious manner to disparage. Other non-disparaging source material was not provided.

References

^ ^a ^b Cite error: The named reference :0 was invoked but never defined (see the help page).
^ "Gilead's Patent Loss to Merck Started With a Broken Friendship". {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)

[:0-1] Cite error: The named reference :0 was invoked but never defined (see the help page).

[2] "Gilead's Patent Loss to Merck Started With a Broken Friendship". {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)

[1]

[2]